Hanall Biopharma Launches 'Glucoph ER Tablets,' a Diabetes Treatment with Reduced Pill Size

Hanall Biopharma Glucop Free Extended-Release Tablets.

[Asia Economy Reporter Lee Gwanju] HanAll Biopharma announced on the 20th that it has launched 'Glucophree Sustained-Release Tablets' (500 mg, 750 mg, 1000 mg) with reduced pill size for patients' convenience.

Glucophree Sustained-Release Tablets (active ingredient metformin) are a first-line treatment for adult patients with type 2 diabetes whose blood sugar control is insufficient through diet and exercise therapy. This product is an improved successor to HanAll Biopharma's 'Glucodown OR Sustained-Release Tablets,' launched in 2007.

Glucophree Sustained-Release Tablets reduce the size by up to 15% compared to Glucodown OR Sustained-Release Tablets, allowing patients who had difficulty swallowing the previous pills to take them more easily. Additionally, the optimized drug release system reduces the dosing frequency from three times to once a day, improving convenience for diabetic patients who need to take multiple medications at once. It is also advantageous that prescriptions can be tailored to patients' conditions with three different dosages available.

Seungsoo Han, Head of Development at HanAll Biopharma, said, “Based on the long-standing experience and know-how of our technology research institute in developing sustained-release formulations, we are striving to improve patients' convenience and medication adherence by developing new products with reduced tablet sizes. We plan to strengthen our position in the diabetes treatment market through the even smaller Glucophree Sustained-Release Tablets.”

Metformin is widely used as a first-line treatment for type 2 diabetes due to its blood sugar-lowering effect, relatively few side effects, and low risk of hypoglycemia. As of last year, the domestic metformin market recorded approximately 82 billion KRW.

This content was produced with the assistance of AI translation services.